Cadrenal Therapeutics Inc expected to post a loss of $1.64 a share - Earnings Preview

Cadrenal Therapeutics

07/05/2025 21:02

Cadrenal Therapeutics Inc CVKD.OQ CVKD.O is expected to show no change in quarterly revenue when it reports  results on May 9 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Cadrenal Therapeutics Inc is for a loss of $1.64 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $32.00​, above​ its last closing price of $15.68. ​​​

This summary was machine generated May 7 at 20:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)